According to the author from a number of overseas media, on June 27th, Swiss genetic editing startup CRISPR Therapeutics announced the completion of the B round of financing. So far the company's total financing has reached 140 million US dollars.
.jpg)
The round of financing was funded by Vertex Pharmaceuticals and Bayer Global Investments as strategic partner of the company, followed by institutional investors and some medical funds, including Franklin Templeton Investments, New Leaf Venture Partners, Clough Capital Partners and Wellington Capital Management LLP. Other life sciences funds. Guggenheim Securities is the financial advisor to CRISPR Therapeutics, and Vischer AG and Goodwin Procter act as legal counsel for the transaction.
CRISPR Therapeutics is a gene editing company that develops genetic drugs for a variety of diseases through its CRISPR/Cas9 gene editing platform to study the treatment of diseases such as cystic fibrosis, blindness, blood diseases and congenital heart disease. CRISPR/Cas9 is a revolutionary technology that allows for direct and accurate gene editing. The company's multidisciplinary research team includes world-class researchers and drug developers who are investigating the use of this technology to develop human disease treatment technologies for a variety of diseases. The company's scientific founder, Emmanuelle Charpentier, holds a patent for the CRISPR/Cas9 gene editing technology and he was involved in the development of the CRISPR/Cas9 gene editing technology.
“We are very pleased to introduce these top institutional investors,†said Rodger Novak, CEO of CRISPR Therapeutics. “And our investment in Vertex and Bayer, our strategic partner, we believe this will lay a solid foundation for the CRISPR/Cas9 gene editing technology and accelerate Its clinical transformation process, as well as the expansion of the R&D team in Cambridge, Massachusetts."
Previously, CRISPR Therapeutics and the research team supported by Novartis of the University of Pennsylvania had a fierce battle for cancer CAR-T technology. But Novartis ended the dispute by paying taxes and patent taxes. In the end, this patent dispute did not affect all CRISPR-Cas9 startups due to the participation of many lawyers. Novak claims that the dispute has not affected the pharmaceutical and biotech companies that work with them, and venture capitalists are more likely to see a more positive side.
It is reported that Caribou Biosciences, Editas ($EDIT), Intellia ($NTLA), Novartis ($NVS) and CRISPR Therapeutics are world-class companies in the field of CRISPR/Cas9 gene editing, all in pre-clinical trials, but the respective diseases It is different. These companies are racing to switch from preclinical to clinical trials faster.
“CRISPR/Cas9 is a significant breakthrough in the exploitation of the root causes of many diseases through gene editing technology. We are very happy to work with partners from the academic and industrial CRISPR Therapeutics who have set a very challenging goal. -- Applying CRISPR/Cas9 technology to the clinic," said a partner at CRISPR Therapeutics.
As early as last October, CRISPR Therapeutics signed a four-year strategic partnership agreement with Vertex Pharmaceuticals to develop gene therapy solutions using CRISPR/Cas9 technology. As part of the program, Vertex agreed to provide a $75 million advance cash investment and a $30 million equity investment in CRISPR Therapeutics.
Electronic Lock Safe Box,Home Security Electronic Lock Box,Electronic Key Safes,Electronic Lock
Hebei Tiger Brand Group Jia Bao Cabinet Industry Co. LTD , https://www.cntigersafe.com